key: cord-1038473-lxhh7uab authors: Tam, Lai‐Shan; Tanaka, Yoshiya; Handa, Rohini; Li, Zhanguo; Lorenzo, Jose Paulo; Louthrenoo, Worawit; Hill, Catherine; Pile, Kevin; Robinson, Philip C.; Dans, Leonila F.; Hsu, Li Yang; Lee, Sang‐Min; Cho, Jiacai; Hasan, A. T. M. Tanveer; Salim, Babur; Samreen, Saba; Shaharir, Syahrul Sazliyana; Wong, Priscilla; Chau, Jeffrey; Danda, Debashish; Haq, Syed Atiqul title: Updated APLAR consensus statements on care for patients with rheumatic diseases during the COVID‐19 pandemic date: 2021-05-04 journal: Int J Rheum Dis DOI: 10.1111/1756-185x.14124 sha: f623c8a173c6b39333f6b83d330664cfd6e90e86 doc_id: 1038473 cord_uid: lxhh7uab AIM: To update previous guidance of the Asia Pacific League of Associations for Rheumatology (APLAR) on the management of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID‐19) pandemic. METHODS: Research questions were formulated focusing on diagnosis and treatment of adult patients with RMD within the context of the pandemic, including the management of RMD in patients who developed COVID‐19. MEDLINE was searched for eligible studies to address the questions, and the APLAR COVID‐19 task force convened 2 meetings through video conferencing to discuss its findings and integrate best available evidence with expert opinion. Consensus statements were finalized using the modified Delphi process. RESULTS: Agreement was obtained around key aspects of screening for or diagnosis of COVID‐19; management of patients with RMD without confirmed COVID‐19; and management of patients with RMD with confirmed COVID‐19. The task force achieved consensus on 25 statements covering the potential risk of acquiring COVID‐19 in RMD patients, advice on RMD medication adjustment and continuation, the roles of telemedicine and vaccination, and the impact of the pandemic on quality of life and on treatment adherence. CONCLUSIONS: Available evidence primarily from descriptive research supported new recommendations for aspects of RMD care not covered in the previous document, particularly with regard to risk factors for complicated COVID‐19 in RMD patients, modifications to RMD treatment regimens in the context of the pandemic, and COVID‐19 vaccination in patients with RMD. In May 2020, the Asia Pacific League of Associations for Rheumatology (APLAR) published a position statement on the care of patients with rheumatic and musculoskeletal diseases (RMD) during the coronavirus disease 2019 (COVID- 19) pandemic. 1 The document was borne from the urgency to provide a preliminary rheumatology management guide for Asia Pacific practitioners as the rapid spread of COVID-19 generated challenges unique to the treatment of rheumatic disease. The lack of data from quantitative research on COVID-19 before the May publication of the APLAR statement, especially data that centers on patients with RMD, precluded our guideline working group, the APLAR COVID-19 task force, from providing specific recommendations. Since then, new information from both quantitative and qualitative research has emerged from globally conducted dynamic research efforts. We aimed to review all available new and pertinent evidence, and to update our preliminary statement by developing consensus recommendations for the management of patients with RMD during the COVID-19 pandemic. This document presents our findings and the resultant 25 consensus statements. The recommendations together aim to provide a much-needed practical guide to clinical decision-making of the healthcare practitioner caring for RMD patients during this time. They do not include recommendations on the specific management of COVID-19 infection. The APLAR COVID-19 task force consisted of 21 members including specialists in the fields of rheumatology, pulmonology, and Medical subject headings (MeSH) for "rheumatic diseases" and "COVID-19" were used in the search strategy, along with the appropriate MeSH terms for the concepts of prevention, diagnosis, screening, and treatment. For drug therapy, the following key words and their related terms were included in the search: non-steroidal anti-inflammatory drugs (NSAIDs), glucocorticoids, conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), biological DMARDs (bDMARDs), and targeted synthetic DMARDs (ts-DMARDs). With the understanding that controlled trials may have not yet been completed, searches were not limited to randomized controlled trials but also included other study types such as noncontrolled trials, cohort studies, other comparative studies, case series, and case reports. Other consensus documents and abstracts were also retrieved and reviewed. Searches were also not limited to the English language to broaden the yield of studies from across the globe. The members were grouped according to the identified core RMD topics and their corresponding research questions. Each group was instructed to review the evidence, then draft relevant consensus best available evidence with expert opinion. Consensus statements were finalized using the modified Delphi process. Results: Agreement was obtained around key aspects of screening for or diagnosis of COVID-19; management of patients with RMD without confirmed and management of patients with RMD with confirmed COVID-19. The task force achieved consensus on 25 statements covering the potential risk of acquiring COVID-19 in RMD patients, advice on RMD medication adjustment and continuation, the roles of telemedicine and vaccination, and the impact of the pandemic on quality of life and on treatment adherence. Available evidence primarily from descriptive research supported new recommendations for aspects of RMD care not covered in the previous document, particularly with regard to risk factors for complicated COVID-19 in RMD patients, modifications to RMD treatment regimens in the context of the pandemic, and COVID-19 vaccination in patients with RMD. APLAR guidance, Asia Pacific, consensus, rheumatic disease, SARS-CoV-2 statements, all for presentation and discussion during pre-planned video conferences. The first meeting was held on 10 October 2020 to discuss, refine, and vote on the statements. The quality of evidence supporting each statement was evaluated using the evidence-assessment frameworks prescribed by the Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system. 2,3 Using the modified Delphi approach to achieve expert group consensus, the meeting attendees provided feedback on the evidence presentation and the proposed statements. An online poll launched during the meeting allowed them to indicate their levels of agreement with the proposed statements by choosing among 5 options: 1, accept completely; 2, accept with some reservations; 3, accept with major reservations; 4, reject with reservations; and 5, reject completely. The draft statement was endorsed as a final consensus recommendation when the combined percentages for the responses of "accept completely" and "accept with some reservations" totaled ≥80% of votes among the attendees. The group agreed on a strength of recommendation where applicable, that is, for statements recommending a course of action. Discussion of the research questions, their associated evidence, and proposed statements continued during the second meeting, which was held on 1 November 2020. Further clarifications on unresolved matters during the first meeting were carried over to the second meeting. The panel members were encouraged to review additional references that emerged during the interval between the 2 meetings. Grading of the statements and online voting proceeded for the remainder of topics and their draft statements. Consensus was again established at ≥80% agreement. Some proposed statements were considered at the time to have insufficient supporting evidence. These "expert opinion" statements were made available to the task force members online for final review and voting after the second meeting. The task force achieved consensus on 25 statements ( Table 2) . Nine of the statements were deemed "expert opinion" statements, given the paucity of supporting evidence on these topics. 3. C12. It is recommended that patients with RMD receive an approved SARS-CoV-2 vaccine as soon as it becomes available to them. (100% agreement, expert opinion, strong recommendation). should receive vaccination based on current country, regional and/or international guidelines. (100% agreement, expert opinion, strong recommendation). The clinical presentation of COVID-19 among RMD patients is generally similar to its presentation in non-rheumatic patients. Fever, cough, sore throat, and dyspnea manifest in the same manner. 6, 55, 56 Laboratory parameters were also found to be similar, except for higher white blood cell count at presentation and lower peak ferritin levels in RMD patients. 6 The WHO presented low-certainty evidence that patients on long-term ACEi/ARB therapy are not at a higher risk of poor outcomes from COVID-19. 60 In addition, the only randomized trial data to date did not show clinical benefit with discontinuing long-term ACEi/ARB treatment for hospitalized, COVID-19-positive patients. The pandemic has also impacted the QoL of RMD patients. They should provide or recommend support for mental and physical functioning, in addition to managing RMD. To update the initial APLAR position statement, the COVID-19 task force was mandated to address important concerns in the care of the patient with RMD that arose from the rapid changes to healthcare due to the pandemic. Patients with RMD have also been coping with the challenges of adhering to infection prevention directives while working with their treating rheumatologists to control their disease. Based on currently available best evidence, our group has updated previous APLAR guidance by: • noting the potential risk of RMD patients for complicated COVID-19 and listing probable risk factors • describing the clinical manifestations of COVID-19 that are similar to RMD features • reviewing the initial findings of potential risks associated with specific RMD therapies and providing some guiding principles for medication adjustment, and • highlighting the role of vaccination, the role of telemedicine, changes in RMD treatment adherence, and the importance of changes to QoL during the pandemic. The vibrant research landscape has, to date of this publication, produced a great volume of descriptive research that has helped to provide a better understanding of COVID-19. Importantly, numerous studies have also covered how aspects of RMD management are impacted by the pandemic. However, most of the data from publications summarized here were considered as low-quality to moderate-quality evidence. Our audience should regard this guidance judiciously and continue to monitor for more robust, definitive data from randomized controlled trials and larger, population-based studies; the APLAR COVID-19 task force will do the same, updating this document in 2021 as new evidence becomes available. Medical writing and editorial support were provided by Dr Jose Miguel (Awi) Curameng and Dr Pia Villanueva of MIMS (Hong Kong) Limited. non-financial support from Bristol Myers Squibb, outside the submitted work. The remaining authors disclose no conflicts of interest. L-S Tam, Y Tanaka, R Handa and SA Haq planned the meeting and prepared the clinical questions. All task force members contributed Care for patients with rheumatic diseases during COVID-19 pandemic: a position statement from APLAR Going from evidence to recommendations GRADE guidelines: 3. Rating the quality of evidence Prevalence and clinical outcomes of COVID-19 in patients with autoimmune diseases: a systematic review and meta-analysis Clinical features of rheumatic patients infected with COVID-19 in Wuhan, China Clinical characteristics and outcomes of patients with coronavirus disease 2019 (COVID-19) and rheumatic disease: a comparative cohort study from a US 'hot spot Coronavirus disease 2019 outcomes among patients with rheumatic diseases 6 months into the pandemic Clinical outcomes of hospitalised patients with COVID-19 and chronic inflammatory and autoimmune rheumatic diseases: a multicentric matched cohort study Brescia Rheumatology COVID-19 Study Group. COVID-19 in patients with rheumatic diseases in northern Italy: a single-centre observational and case-control study Clinical characteristics of 17 patients with COVID-19 and systemic autoimmune diseases: a retrospective study Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry Factors associated with COVID-19-related death using OpenSAFELY Identifying rheumatic disease patients at high risk and requiring shielding during the COVID-19 pandemic Incidence of COVID-19 in patients with rheumatic disease: is prior health education more important than shielding advice during the pandemic? Safety of synthetic and biological DMARDs: a systematic literature review informing the 2019 update of the EULAR recommendations for the management of rheumatoid arthritis Factors associated with COVID-19-related death in people with rheumatic diseases: results from the COVID-19 Global Rheumatology Alliance physician-reported registry Centers for Disease Control and Prevention. Appendices: COVID-19 (Coronavirus Disease). Available at EULAR provisional recommendations for the management of rheumatic and musculoskeletal diseases in the context of SARS-CoV-2 Preliminary recommendations of the German Society of Rheumatology (DGRh eV) for the management of patients with inflammatory rheumatic diseases during the SARS-CoV-2/COVID-19 pandemic American College of Rheumatology Guidance for the management of rheumatic disease in adult patients during the COVID-19 Pandemic: version 2 Experiences of patients with rheumatic diseases in the United States during early days of the COVID-19 pandemic Einstellung von Patienten mit entzündlich-rheumatischen Erkrankungen zur immunsuppressiven Therapie im Rahmen der COVID-19 Pandemie -eine Situationsanalyse [A cross sectional study on patients with inflammatory rheumatic diseases in terms of their compliance to their immunsuppressive medication during COVID-19 pandemic Treatment adherence of patients with systemic rheumatic diseases in COVID-19 pandemic Incidence of COVID-19 in patients with rheumatic diseases treated with targeted immunosuppressive drugs: what can we learn from observational data? Arthritis Rheumatol Treatment adherence behaviours in rheumatic diseases during COVID-19 pandemic: a Latin American experience Adherence to medication in patients with rheumatic diseases during COVID-19 pandemic Perspectives of patients with rheumatic diseases in the early phase of COVID-19 Telemedicine for patients with rheumatic diseases: Systematic review and proposal for research agenda Management of patients with inflammatory rheumatic diseases: telemedicine and rheumatologists challenged in the era of COVID-19. Front Public Health Patient acceptance of using telemedicine for follow-up of lupus nephritis in the COVID-19 outbreak [published online ahead of print World Health Organization. DRAFT landscape of COVID-19 candidate vaccines -10 US Food and Drug Administration US Food and Drug Administration. Moderna COVID-19 Vaccine EUA Letter of Authorization The Advisory Committee on immunization practices' interim recommendation for allocating initial supplies of COVID-19 vaccine -United States, 2020. MMWR Vaccine considerations for people with underlying medical conditions COVID-19: the green book, chapter 14a COVID-19 vaccination in immunocompromised patients Vaccination against SARS-CoV-2 in patients with rheumatic diseases: doubts and perspectives Guiding principles for immunization activities during the COVID-19 pandemic. Interim guidance: 26 Interim guidance for routine and influenza immunization services during the COVID-19 pandemic Altered Immunocompetence General Best Practice Guidelines for Immunization: Best Practices Guidance of the Advisory Committee on Immunization Practices (ACIP) 2019 update of EULAR recommendations for vaccination in adult patients with autoimmune inflammatory rheumatic diseases Autoimmune and rheumatic musculoskeletal diseases as a consequence of SARS-CoV-2 infection and its treatment On the alert for cytokine storm: immunopathology in COVID-19 Myositis as a manifestation of SARS-CoV-2 Classification of the cutaneous manifestations of COVID-19: a rapid prospective nationwide consensus study in Spain with 375 cases Large-vessel stroke as a presenting feature of Covid-19 in the young Giant cell arteritis and COVID-19: similarities and discriminators. A systematic literature review Guillain-Barré syndrome related to COVID-19 infection Guillain-Barré syndrome associated with SARS-CoV-2 An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic: an observational cohort study Impact of antirheumatic drugs and steroids on clinical course and prognosis of COVID-19 COVID-19 in rheumatic diseases in Italy: first results from the Italian registry of the Italian Society for Rheumatology (CONTROL-19) COVID-19 with rheumatic diseases: a report of 5 cases EMA gives advice on the use of nonsteroidal anti-inflammatories for COVID-19 World Health Organization. The use of non-steroidal antiinflammatory drugs (NSAIDs) in patients with COVID-19: Scientific brief Non-steroidal anti-inflammatory drugs and susceptibility to COVID-19 World Health Organization. COVID-19 and the use of angiotensin-converting enzyme inhibitors and receptor blockers: Scientific Brief Continuing versus suspending angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: Impact on adverse outcomes in hospitalized patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-The BRACE CORONA Trial COVID-19 prevention and treatment: a critical analysis of chloroquine and hydroxychloroquine clinical pharmacology National registry for patients with inflammatory rheumatic diseases (IRD) infected with SARS-CoV-2 in Germany (ReCoVery): a valuable mean to gain rapid and reliable knowledge of the clinical course of SARS-CoV-2 infections in patients with IRD COVID-19 in patients with inflammatory arthritis: a prospective study on the effects of comorbidities and disease-modifying antirheumatic drugs on clinical outcomes Covid-19 in immune-mediated inflammatory diseases -case series from New York Baricitinib plus remdesivir for hospitalized adults with Covid-19 Long-term hydroxychloroquine use in patients with rheumatic conditions and development of SARS-CoV-2 infection: a retrospective cohort study Clinical course of COVID-19 in a series of patients with chronic arthritis treated with immunosuppressive targeted therapies Clinical outcomes of COVID-19 in patients taking tumor necrosis factor inhibitors or methotrexate: a multicenter research network study Susceptibility and severity of COVID-19 in patients treated with bDMARDS and tsDMARDs: a population-based study A complex COVID-19 case with rheumatoid arthritis treated with tocilizumab Severe COVID-19-associated pneumonia in 3 patients with systemic sclerosis treated with rituximab Rituximab for granulomatosis with polyangiitis in the pandemic of covid-19: lessons from a case with severe pneumonia Increased risk for severe COVID-19 in patients with inflammatory rheumatic diseases treated with rituximab but not TNF antagonists, are associated with adverse COVID-19 outcomes in patients with inflammatory bowel diseases: results from an International Registry Accumulating evidence suggests anti-TNF therapy needs to be given trial priority in COVID-19 treatment The potential for repurposing anti-TNF as a therapy for the treatment of COVID-19 Efficacy of tocilizumab in patients hospitalized with Covid-19 Dexamethasone in hospitalized patients with Covid-19 -preliminary report Corticosteroids for COVID-19: living guidance Temporal dynamics in viral shedding and transmissibility of COVID-19 Presymptomatic SARS-CoV-2 infections and transmission in a skilled nursing facility Duration of isolation and precautions for adults with COVID-19 Shedding of infectious virus in hospitalized patients with coronavirus disease-2019 (COVID-19): duration and key determinants Discontinuation of transmission-based precautions and disposition of patients with COVID-19 in healthcare settings European Foundation for the Improvement of Living and Working Conditions (Eurofound). Living, working and COVID-19 Healthrelated quality of life and its associated factors in COVID-19 patients Rheumatic disease-related symptoms during the height of the COVID-19 pandemic COVID-19 prevalence and the impact on quality of life from stringent social distancing in a single large UK rheumatology centre